Executive Summary
A dedicated leaflet-splitting catheter cleared its first real-world stress test: in 150 U.S. valve-in-valve TAVR patients treated with Pi-Cardia's ShortCut device, coronary obstruction dropped to 2% in a cohort where 87% were flagged high-risk on CT, but two deaths from left ventricular perforation traced to the stiff wire platform flag that this is not a benign add-on. A 350-patient CT scoring study pushes peripheral atherosclerosis burden as a pre-TAVR CAD screen, and a 158-patient M-TEER series hardens TAPSE/PASP <0.37 as the survival discriminator that TAPSE alone misses. Redo-TAVR is now a mainstream problem the field is arming itself for, which tightens the case for planning the second procedure at the first.
- ShortCut leaflet modification for ViV TAVR: 2% coronary obstruction, 1.3% conversion to surgery, 2% mortality across 150 patients — feasibility confirmed, wire-related perforation risk explicit [NOTABLE]
- Hostile PAD score on pre-TAVR CT excluded obstructive CAD with 91% sensitivity and 80.6% accuracy (N=350), and high scores doubled all-cause mortality (CRM)
- RV-PA uncoupling (TAPSE/PASP <0.37 mm/mmHg) present in 32% of M-TEER patients drove 3-year survival from 62% to 51% (BMC Cardiovasc Disord)
- Anteris (AVR.AX) up 5.5% and +97% over six months on the DurAVR narrative, ahead of any pivotal readout (Citeline)
- Abbott opened a 1,000-patient post-market TriClip registry (NCT07586995), extending real-world surveillance of the ESC 2025 Class IIa transcatheter TR pathway (ClinicalTrials.gov)
What to watch: Edwards Lifesciences reports Q2 earnings July 23 (EPS est $0.74, revenue est $1.70B), the first read on TAVR volumes since ESC 2025 lowered the TAVI-preferred age threshold to 70.
Aortic Valve (TAVR/TAVI)
Makkar and colleagues published a 150-patient U.S. real-world series of the Pi-Cardia ShortCut leaflet modification device in valve-in-valve TAVR. The primary risk signal is encouraging: coronary obstruction dropped to 2% despite 87.3% of patients meeting CT-based high-risk criteria, with a 1.3% surgical conversion rate. Two of three deaths were LV perforations "likely related to the stiffer wire platform required for leaflet splitting" — a mechanistic complication BASILICA and chimney stenting don't share. The series is non-randomized, single-arm, with no comparator and a 9-month enrollment window. ACC/AHA 2020 still favors SAVR under 65 on durability grounds; ESC 2025 lowered the TAVI-preferred threshold to 70, and the lifetime management calculus these ShortCut data enable is exactly the argument the ESC used to justify that shift. Fukuhara's Annals editorial reframes post-TAVI reintervention as a moving target in an era where the denominator, valve generation, and follow-up all shift under the analyst — a useful corrective against treating any single ViV series as definitive.
A Hostile PAD score study (N=350) also earns mention: 91% sensitivity to exclude obstructive CAD from the pre-TAVR CT alone, with high scores doubling mortality risk. If it validates in a prospective cohort, invasive angiography before TAVR shrinks. Same-day discharge TAVI gets a state-of-the-art review today; randomized data don't yet exist to support that practice at scale.
Mitral Valve (MitraClip, PASCAL, TMVR)
RV-PA coupling is the M-TEER prognosticator that keeps refusing to be simplified. Ausbuettel and colleagues analyzed 158 consecutive M-TEER patients and showed that TAPSE/PASP <0.37 mm/mmHg — present in 32% of patients — separated 3-year survival at 51% vs 62%, while TAPSE <18 mm alone failed as a discriminator. The study is single-center, observational, and relies on echocardiographic-only PASP estimation. Procedural success was equivalent across RV-PA coupling groups (OR 0.95), so the finding is about trajectory, not technical feasibility. ESC 2025 elevated TEER for ventricular secondary MR to Class I, LOE A on the strength of COAPT, RESHAPE-HF2, and the resolved MITRA-FR discrepancy; ACC/AHA 2020 remains at Class IIa. Neither guideline embeds RV-PA coupling into the selection algorithm — this dataset argues it should, and the ESC's Class I upgrade makes that omission more consequential, not less.
Separately, Harb and colleagues at Cleveland Clinic report initial experience with Philips 3D automated color flow MR quantification, a fluid-dynamics-plus-AI segmentation approach that sidesteps PISA's hemispheric and holosystolic assumptions. Early series, no validation cohort yet — but PISA has been the field's known-flawed workhorse for two decades and a direct replacement is overdue. A case report flags device-related thrombosis after combined MitraClip + LAAC in a patient presenting with ischemic stroke, a reminder that the prothrombotic transition post-combined procedure remains poorly characterized.
Tricuspid Valve (TriClip, TTVR)
The transcatheter TR field has moved from pivotal trial to real-world surveillance, and Abbott just opened the largest post-market TriClip dataset yet. NCT07586995 is a 1,000-patient recruiting post-market study of tricuspid TEER, sponsored by Abbott Medical Devices and initiated July 2. This registry will either confirm or complicate the ESC 2025 Class IIa, LOE A recommendation for transcatheter TR treatment in high-risk symptomatic patients — a recommendation grounded in TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II, all driven by patient-reported outcomes rather than mortality. ACC/AHA 2020 did not address transcatheter TR at all; the next U.S. update will need to reconcile the gap. The registry will not resolve the surgical-vs-transcatheter question because it carries no surgical arm — a real limitation. ESC 2025 also upgraded TV surgery for symptomatic severe primary TR to Class I and expanded the case for earlier referral, on the argument that historical isolated TV surgery mortality of 8–20% reflected too-late referral rather than an inherent surgical ceiling. Whether transcatheter TR treatment serves patients who would benefit from earlier surgery, or patients who are genuinely inoperable, is a question this registry is not designed to answer.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. Fukuhara's Annals commentary makes the sharpest point available: post-TAVI reintervention analysis is a moving target because valve generations, patient risk profiles, and follow-up windows are all in flux simultaneously. Any TAVR-vs-SAVR durability claim built on 5-year data from earlier device generations is analyzing a device that isn't being implanted today — a point ESC 2025 acknowledged when it noted patients <70 remain poorly represented in the RCT evidence base underpinning its own age-threshold shift.
Device & Technology
Two device stories today, opposite ends of the maturity curve. The ShortCut leaflet modification catheter is post-FDA-clearance (September 2024) and generating its first real-world outcomes — a dedicated tool replacing the improvised BASILICA workflow. On the earlier end, Anteris Technologies' single-piece DurAVR biomimetic valve gets a fresh feature piece — narrative ahead of pivotal data, with a single analyst covering the stock at a target of A$13.00 that sits below the current price. Also worth flagging: a JACC Case Reports piece on balloon sizing for BAV TAVR in tapered type-1 morphology, arguing predilatation with contrast injection can disambiguate the annular-vs-supra-annular size trade-off. Two patients, technique-level, not a trial. BAV remains ACC/AHA IIb and ESC IIb — sizing refinements don't change that classification.
Regulatory & Policy
Cardiovascular Business flags forthcoming TAVR policy changes in its weekly roundup without specifics. CMS TAVR volume-requirement revisions have been telegraphed and would reshape access at community centers.
Industry & Market
Two vectors today. Positive: broad medtech tape strength on July 2, with EW (+2.59%), MDT (+5.04%), ABT (+3.49%), and BSX (+4.83%) all bid; TD Cowen named Edwards a top medtech pick. Negative undertone: Boston Scientific is being framed as leaning harder on cardiovascular growth even as its stock sits down 52.7% over six months, a print that will attract questions on the July 29 call.
Financial Analysis
Edwards' TD Cowen upgrade and 52-week high land in the same tape as the ESC 2025 age-threshold shift — the guideline change that widens the TAVI-preferred zone in Europe by a decade. That's the clinical explanation the market is pricing ahead of the July 23 print. The counterweight sits inside today's clinical literature: Fukuhara's reintervention commentary and the ShortCut real-world experience both underscore that lifetime management costs — second procedures, dedicated devices, imaging, planning — are accumulating on the TAVR side of the ledger. The ShortCut technology belongs to Pi-Cardia (private), but the workflow it enables extends the addressable ViV market that Edwards and Medtronic both compete in. BSX at -52.7% over six months and ABT at -23.7% reflect broader medtech sentiment, not structural heart deterioration — both franchises remain well-positioned against the ESC 2025 M-TEER Class I and transcatheter TR Class IIa expansions.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $94.37, +2.59% on the day; six-month change +12.12%, sitting at 52-week high $94.47
- Market cap $54.3B; trailing P/E 51.0, forward P/E 28.0; beta 0.87
- Analyst target $97.31 (range $84–$110, 26 analysts); consensus buy
- Q2 earnings July 23: EPS est $0.74, revenue est $1.70B
- TD Cowen named EW a top medtech pick; the setup reflects ESC 2025 tailwind plus continued TAVR share leadership. The July 23 read will focus on whether early asymptomatic AS intervention (post-EARLY TAVR) is yet visible in volume
Medtronic (MDT)
- Close $83.19, +5.04% on the day; six-month change -13.08%
- Market cap $106.5B; trailing P/E 22.3, forward P/E 13.0; beta 0.60
- Analyst target $97.77 (range $78–$121, 26 analysts); consensus buy
- Next earnings August 18: EPS est $1.39, revenue est $9.55B
- Evolut Low Risk long-term data continue to underpin the TAVR franchise. Six-month underperformance reflects diversified-medtech drag, not structural heart weakness
Abbott (ABT)
- Close $95.40, +3.49% on the day; six-month change -23.70%
- Market cap $166.2B; trailing P/E 26.7, forward P/E 15.8; beta 0.62
- Analyst target $116.72 (range $92–$135, 25 analysts); consensus buy
- Q2 earnings July 16: EPS est $1.28, revenue est $12.52B
- New 1,000-patient TriClip post-market registry launched today (NCT07586995) extends the transcatheter TR moat. MitraClip franchise sits inside ESC 2025 Class I for ventricular SMR
Boston Scientific (BSX)
- Close $45.14, +4.83% on the day; six-month change -52.72% (52-week range $42.25–$109.50)
- Market cap $67.1B; trailing P/E 18.9, forward P/E 12.1; beta 0.58
- Analyst target $75.00 (range $55–$106, 29 analysts); consensus strong buy
- Q2 earnings July 29: EPS est $0.83, revenue est $5.37B
- Six-month drawdown looks discretionary rather than fundamental; ACURATE neo2 program and structural heart pipeline remain intact, and analyst dispersion is unusually wide
Anteris Technologies (AVR.AX)
- Close A$14.77, +5.50% on the day; six-month change +96.93%
- Market cap A$1.4B; forward P/E negative (pre-commercial); beta 0.73
- Single analyst covers with target A$13.00 — below current price
- DurAVR profile piece today (Citeline) extended the narrative bid. The valuation prices confidence ahead of pivotal readouts — high beta to a single trial
Market outlook: Structural heart tape strength July 2 tracks the ESC 2025 guideline expansion more than any single trial. The July 16 (ABT), July 23 (EW), and July 29 (BSX) prints will together triangulate whether the guideline shifts are showing up in procedure volumes yet, or whether the market is paying for a 2027 story today.
Clinical Trial Updates
Tricuspid Repair
- NCT07586995 — A Post-Market Assessment of the Safety and Performance of the TriClip™ System. Status: recruiting. Phase: N/A. Enrollment target 1,000. Sponsor: Abbott Medical Devices. Intervention: tricuspid TEER. Newly listed July 2 — this is the largest post-market TriClip surveillance dataset to date and the U.S. clinical-community bridge to the ESC 2025 Class IIa, LOE A transcatheter TR recommendation. Watch for enrollment pace and any interim safety readouts.
No new status changes today in landmark aortic (PARTNER, Evolut Low Risk, EARLY TAVR), mitral repair (COAPT, RESHAPE-HF2, REPAIR-MR), mitral replacement (APOLLO), or tricuspid replacement (TRISCEND II) programs.
Social & Conference Highlights
TCTMD flags the Second Universal Definition of Heart Failure, restructured around phenotype and etiology — relevant to structural heart because the ventricular vs atrial secondary MR distinction and RV-PA coupling frameworks (see today's M-TEER data) map directly onto phenotype-first thinking. Community rollout: Pikeville Medical Center completed its first solo MitraClip case, a small marker of continued diffusion into the community hospital tier.
The next catalyst is Abbott's July 16 earnings, where the TriClip real-world enrollment ramp and MitraClip growth on the strength of ESC 2025's Class I upgrade should both be quantified. Beyond that, the July 23 Edwards print becomes the first clean read on whether guideline expansion translates into a procedure-volume signal or remains 2027 optionality.
— E. Nolan Beckett, MD